Title: B-OK: A Visual and Tactile Tool for HIV Treatment Adherence Support in a United States Urban Center

Aaron RICHTERMAN,^{1,2} Tamar KLAIMAN,³ Daniel PALMA,¹ Eric RYU,³ Laura SCHMUCKER,³ Katherine VILLARIN,¹ Gabrielle GROSSO,¹ Kathleen A BRADY,⁴ Harsha THIRUMURTHY,^{2,3} Alison BUTTENHEIM^{2,3,5}

Keywords: HIV, Treatment Adherence Support, Visual Aid, Behavioral Economics

Abbreviations: ART, antiretroviral therapy; EHE, Ending the HIV Epidemic; HIV, Human Immunodeficiency Virus; MCM, medical case manager; PLWH, person/people living with HIV; PSI, Population Sciences International; TAS, treatment adherence support; U=U, undetectable=untransmittable

Word count: 3980 Number of references: 40 Number of tables: 2 Number of figures: 2

Corresponding Author: Aaron Richterman, MD, MPH; Hospital of the University of Pennsylvania, 3400 Spruce Street, Philadelphia, PA 19104; e-mail: <u>aaron.richterman@pennmedicine.upenn.edu</u> telephone: 2674417915; ORCID: 0000-0001-7920-7191

Affiliations:

¹ Division of Infectious Diseases, Department of Medicine, University of Pennsylvania, Philadelphia, Pennsylvania, USA

² Leonard Davis Institute of Health Economics, University of Pennsylvania, Philadelphia, Pennsylvania, USA

³ Department of Medical Ethics and Health Policy, University of Pennsylvania, Philadelphia, Pennsylvania, USA

⁴ Division of HIV Health, Philadelphia Department of Public Health, Philadelphia, Pennsylvania, USA

⁵ Department of Family and Community Health, University of Pennsylvania, Philadelphia, Pennsylvania, USA

1 Abstract

2 Lack of adherence to antiretroviral therapy (ART) and poor retention in care are significant 3 barriers to ending HIV epidemics. Treatment adherence support (TAS) effectiveness may 4 be constrained by limited awareness and understanding of the benefits of ART, 5 particularly the concepts of treatment as prevention and Undetectable=Untransmittable 6 (U=U), for which substantial knowledge gaps persist. We used mixed methods to evaluate 7 a straightforward visual and tactile tool, the B-OK Bottles ("B-OK"), that incorporates 8 human-centered design and behavioral economics principles and is designed to change 9 and strengthen mental models about HIV disease progression and transmission. We 10 enrolled 118 consenting adults living with HIV who were clients of medical case managers 11 at one of four case management agencies in Philadelphia. All participants completed a 12 pre-intervention survey, a B-OK intervention, and a post-intervention survey. A subset 13 (N=52) also completed qualitative interviews before (N=20) or after (N=32) B-OK. 14 Participants had a median age of 55 years (IQR 47-60), about two-thirds were male sex 15 (N=77, 65%), nearly three-quarters identified as non-Hispanic Black (N=85, 72%), and 16 almost all reported receiving ART (N=116, 98%). Exposure to B-OK was associated with 17 improved awareness and understanding of HIV terminology, changes in attitudes about 18 HIV treatment, and increased intention to rely on HIV treatment for transmission 19 prevention. Insights from qualitative interviews aligned with the quantitative findings as 20 respondents expressed a better understanding of U=U and felt that B-OK clearly 21 explained concepts of HIV treatment and prevention. These findings provide a strong 22 rationale to further evaluate the potential for B-OK to improve TAS for PLWH.

23 Introduction

24 New HIV diagnoses in the United States have plateaued at around 38,000 annually since 25 2013.^{1,2} This lack of progress prompted the United States Department of Health and 26 Human Services to announce a ten-year "Ending the HIV Epidemic" (EHE) initiative in 27 2019.³ The goal of EHE is to reduce new infections by 90% by 2030 through intensified 28 diagnostic, treatment, prevention, and outbreak response efforts in the 48 counties where over half of HIV diagnoses occurred in 2016 and 2017.³ In many settings, including 29 30 Philadelphia — one of the EHE priority jurisdictions — lack of adherence to antiretroviral 31 therapy (ART) and poor retention in care are the most significant barriers to ending the 32 HIV epidemic.⁴ As of 2020, among the 14,873 people living with HIV (PLWH) in 33 Philadelphia who had been in care in the last 5 years, 14% were out of care (accounting 34 for 36% of HIV transmissions), and 11% were in care but not virally suppressed 35 (accounting for 25% of HIV transmissions).³

36 Various treatment adherence support (TAS) interventions administered by clinical 37 providers, case managers, peers, and others have been shown to improve engagement in care and ART adherence.^{5,6} However, TAS effectiveness may be constrained by limited 38 39 awareness and understanding of the benefits of ART, including the benefits of treatment 40 as prevention. Despite multiple landmark studies showing that viral suppression with ART prevents HIV transmission between serodiscordant sexual partners,⁷⁻⁹ and a global 41 42 "Undetectable=Untransmittable" (U=U) campaign designed to translate these findings into a movement to promote ART use,¹⁰ substantial knowledge gaps persist about the 43 44 prevention benefits of ART and U=U remains a challenging concept to convey to individuals in a simple and scalable manner.^{11,12} In Philadelphia, knowledge barriers were 45

46 reported by 79% of PLWH at re-engagement in care, with responses such as "since there 47 is no cure for HIV, why should I go to a doctor?"¹³ Maintaining viral suppression can be 48 an effective motivator for remaining in care and adhering to ART, but only if a PLWH 49 understands and internalizes concepts related to HIV pathogenesis, transmission, and 50 treatment.¹²

51 Behavioral economics insights, which can help explain how people process complex health information and make health-related decisions,¹⁴ may be instrumental in designing 52 53 strategies to improve TAS. For example, behavioral economics research shows that 54 people use simplified cognitive representations of complex concepts, referred to as 55 mental models, during decision-making. Mental models are known to influence beliefs and behavior in many health-related domains,¹⁵⁻²¹ and incorrect mental models may be 56 57 one reason why people do not understand what it means to be virally suppressed, or why 58 they may underestimate the HIV prevention benefits of ART. Interventions aiming to 59 correct mental models about HIV and ART can benefit from the use of other behavioral 60 economics principles, such as presenting information in a salient manner, leveraging 61 framing effects (e.g., health messages may be more effective if they avoid emphasizing 62 disease and vulnerability), and employing analogies to introduce and reinforce new 63 mental models.²²

In this study, we used mixed methods to evaluate a straightforward visual and tactile tool, the B-OK Bottles (hereafter referred to as "B-OK"), that integrates these behavioral economics principles while also drawing on several components of the Extended Process Parallel Model (EPPM) for behavior change communication.²³ B-OK was initially developed for the South African context,²⁴ and in this study we aimed to explore B-OK's

69 potential to improve TAS for PLWH in Philadelphia. We hypothesized that this tool would 70 correct mental models about HIV disease progression and transmission, reframe 71 attention towards taking control of one's health through achieving viral suppression and 72 away from the loss of health, and enhance retention, recall, and comprehension of 73 complex HIV-related information (Figure 1). We further hypothesized that these changes 74 would lead to favorable changes in HIV-related awareness, knowledge, attitudes, 75 intentions, or perceptions, ultimately increasing the likelihood of adherence, retention in 76 care, and viral suppression.

77 Methods

78 Study Design and Population

79 We conducted a mixed methods study using an intervention (QUAN + gual) design.²⁵ We 80 enrolled PLWH who were clients of medical case managers at one of four Ryan White-81 funded case management agencies in Philadelphia: one community-based organization 82 (Bebashi – Transition to Hope) and three clinic-based organizations (Drexel University, 83 Albert Einstein Medical Center, and Temple University). Eligibility criteria required 84 participants to be age 18 years or older and able to speak English or Spanish. Study staff 85 recruited participants presenting for scheduled or unscheduled appointments with their 86 medical case managers, and all study activities were completed on the same day.

All participants completed a pre-intervention survey, B-OK, and a post-intervention survey. A subset of participants also completed qualitative interviews before or after B-OK.

90 The University of Pennsylvania Institutional Review Board approved this study. All

91 participants provided written informed consent. One participant withdrew from the study

92 and was not included in this analysis. All participants received \$25 compensation, and

93 participants completing qualitative interviews received an additional \$25.

94 Intervention

95 B-OK is a non-proprietary tool designed to increase HIV treatment literacy (Figure 2). It 96 was developed using human-centered design principles as part of Population Services 97 International's (PSI) Coach Mpilo project and MINA campaign in South Africa in 98 collaboration with Matchboxology.²⁶ B-OK comprises three bottles filled with colored 99 beads in varying ratios to represent the human body in the context of HIV infection. Black 100 beads symbolize healthy cells, while red beads represent HIV and HIV-infected cells. One 101 bottle has a mix of black and red beads, one has mainly red beads with just a few black 102 beads, and the third has black beads with just one red bead. The mixed bottle represents 103 the body at HIV diagnosis, communicating that even though a PLWH might feel well and 104 conclude that no immediate treatment is required, the presence of red beads indicates 105 that HIV is multiplying, detectable, and transmissible. The bottle with predominantly red 106 beads demonstrates the consequences of delaying or stopping treatment. Conversely, 107 the bottle with only one red bead illustrates that taking ART daily can nearly (but not 108 completely) eliminate HIV, rendering the virus undetectable, untransmittable, and virtually 109 unable to harm a PLWH. We used two sets of bottles — a large set (each bottle measured 110 11 inches tall x 4.5 inches diameter) and a small set (3.75 inches x 1 inch). Both sizes 111 were available during the intervention.

112 We developed a conceptual framework illustrating the hypothesized effects of B-OK on 113 PLWH (Figure 1). The study intervention itself was a 5-minute scripted education session 114 administered by one of three trained study staff who were stationed at clinics or MCM 115 offices (see Supplementary Appendix for script). The session focused on using B-OK to 116 explain the fundamental principles of HIV biology (pathogenesis, transmission, clinical 117 outcomes), the effects and importance of ART, and essential HIV terminology (viral 118 suppression, undetectable viral load, and U=U). Participants were encouraged to 119 examine or hold the bottles and to ask questions.

120 Survey Questionnaires

121 Study staff administered pre- and post-intervention survey questionnaires to all 122 participants. Pre-intervention surveys included guestions about demographics, current ART (none, injectable, or oral), and self-reported number of missed ART doses in the last 123 124 30 days among those on oral ART (i.e., adherence). Pre- and post-intervention surveys 125 included questions about awareness of HIV-related terminology (viral suppression, U=U), 126 knowledge about these terms and the effects of ART on clinical outcomes and 127 transmission risk, attitudes about treatment as prevention and prognosis on ART, 128 intentions about relying upon treatment as prevention as a preventive strategy and 129 intention to use ART generally, and perceptions of HIV illness understanding. Awareness 130 questions were binary (yes or no); other questions used probabilistic scales from zero to 131 ten (ten indicating greater knowledge, certainty, etc.).²⁷ Survey guestions were developed 132 based on items used previously in formative and impact studies of U=U and treatment as prevention interventions.^{12,28-37} Surveys were conducted in English or Spanish. 133

134 Statistical Analyses

135 We used descriptive statistics to summarize participant demographics and ART-related 136 variables. Our co-primary outcomes were the 11 questions about HIV awareness, knowledge, attitudes, intentions, and perception. For each outcome, we reported 137 138 summary statistics of the pre-intervention scores and changes between pre- and post-139 intervention scores. For the awareness variables, we compared the proportions of 140 participants who were aware of viral suppression and U=U before and after the 141 intervention using two-sample, two-tailed z-tests. For all other variables, we used single-142 sample two-tailed t-tests to assess whether the change in the score pre- to post-143 intervention was significantly different from zero. We reported unadjusted p-values, and 144 p-values that were adjusted for 11 multiple comparisons using the Benjamini-Hochberg method.³⁸ We considered p<0.05 to be statistically significant. 145

As a secondary analysis, we assessed changes in outcomes in several key subgroups: whether a participant had a pre-intervention interview (based on the hypothesis that discussion about HIV may influence survey answers); optimal adherence to oral ART (>95% over the last 30 days by self-report); and agency type (community-based or clinicbased). We compared changes in the outcomes between subgroups using two-tailed, two-sample t-tests.

152 Statistical analyses were conducted using Stata version 17 (StataCorp) and R version153 4.2.3 (R Foundation for Statistical Computing).

154 In-Depth Interviews

155 We conducted semi-structured qualitative interviews to explore mental models of HIV 156 biology, treatment, and prevention. We recruited participants consecutively and 157 interviewed them before or after exposure to B-OK. Each group (pre- and post-158 intervention) had a planned sample size of at least 20 interviews. We used purposive 159 selection to ensure inclusion across the agencies. One of three study staff members 160 trained in qualitative research (D.P., G.G., and K.V) conducted the interviews in either 161 English or Spanish. Study staff were not employed by the case management agencies 162 and were not involved in the participants' care. We completed the interviews on the day 163 of enrollment, in person, and in a private space. We audio-recorded all interviews, which 164 were then professionally transcribed by an external company.

165 *Qualitative Analyses*

166 Our codebook was developed using an integrated analysis approach that involved major 167 themes from modified grounded theory and a priori domains related to HIV pathogenesis, 168 treatment, and prevention.³⁹ We used an iterative process to refine and finalize the 169 codebook. Two investigators independently coded transcripts (D.P. and E.R.), double-170 coding 20%. Disagreements were discussed and resolved through consensus. We 171 analyzed the data overall and after stratifying by whether the interview was pre-172 intervention or post-intervention. Qualitative analyses were completed using ATLAS.ti 173 version 23 (ATLAS.ti Scientific Software Development GmbH).

174 **Results**

175 Participant Characteristics

176 We enrolled 118 participants with a median age of 55 years (IQR 47-60) from March to 177 April 2023, with about half (N=55, 47%) recruited from the community-based agency 178 (Table 1). About two-thirds were male sex (N=77, 65%), and the vast majority were cis-179 gender (N=113, 96%) and spoke English as their primary language (N=110, 93%). Nearly 180 three-quarters of the participants identified as non-Hispanic Black (N=85, 72%), with the 181 remainder identifying as Hispanic (N=19, 16%), non-Hispanic white (N=6, 5%), and other 182 or multiple race/ethnicities (N=8, 7%). Almost all participants reported receiving ART, 183 either oral (N=107, 91%) or injectable (N=9, 8%). Among participants receiving oral ART, 184 the median number of reported doses missed out of the last 30 days was zero (IQR 0-2). 185 and 36 (33%) had sub-optimal adherence (i.e., <95% self-reported adherence during the 186 last 30 years)

187 Changes in HIV Awareness and Knowledge, Attitudes, Intentions, and Perceptions After
188 B-OK

189 Before B-OK, just over half of the participants (N=61, 52%) had ever heard of the term 190 viral suppression, and three-quarters (N=88, 75%) recognized the term U=U. Following 191 the intervention, awareness rose to 69% (N=81) and 86% (N=101) for viral suppression 192 and U=U, respectively. These changes were statistically significant based on unadjusted 193 p-values (p=0.01 for viral suppression and p=0.03 for U=U), but only the increase in viral 194 suppression remained significant when adjusted for multiple comparisons (adjusted 195 p=0.02 for viral suppression and adjusted p=0.06 for U=U). On ten-point scales, 196 participants' pre-intervention self-reported understanding about the term viral 197 suppression had a mean of 3.4 (SD 4.1), and U=U had a mean of 6.6 (SD 4.3) (Table 2, 198 Supplementary Figures 1-2). Both significantly increased after B-OK — by 2.4 (SD 4.0)

for viral suppression (p<0.0001; adjusted p=0.001), and 1.4 (SD 3.7) for U=U (p=0.0001;
adjusted p=0.0006).

Participants had high pre-intervention knowledge when asked to imagine a scenario in which a PLWH has an undetectable viral load and estimate the probability that this person would transmit HIV to a sexual partner (pre-intervention mean 2.1, SD 3.3) or be harmed by HIV (pre-intervention mean 2.6, SD 3.6), with neither item significantly changing after the intervention (p=0.94, adjusted p=0.94 for HIV transmission; p=0.74, adjusted p=0.81 for HIV harm) (Supplementary Figures 3-4).

Attitudes about the effectiveness of treatment as prevention (pre-intervention mean 4.3, SD 4.3) and HIV prognosis (pre-intervention mean 3.1, SD 4.1), both significantly improved after exposure to the B-OK bottles (manifesting as decreases in worry) with mean changes of -0.8 (SD 4.4; p=0.05) and -0.8 (SD 3.4; p=0.008), respectively (Supplementary Figures 5-6). After adjustment, changes in attitudes about HIV prognosis remained significant (adjusted p=0.02), while treatment as prevention did not (p=0.08).

Before B-OK, participants reported that they would be unlikely to rely on HIV treatment as a sole preventive strategy, as indicated by their high likelihood of using a condom to prevent sexual HIV transmission even with an undetectable viral load (pre-intervention mean 7.8, SD 3.3) (Supplementary Figure 7). The mean change after the intervention was -1.2 (SD 3.0), representing a statistically significant increase in the likelihood of using HIV treatment as a primary preventive strategy (p=0.0001; adjusted p=0.0006).

Participants' intentions to continue ART were very high at baseline (pre-intervention mean
9.5, SD 1.8), and did not significantly change after the intervention (p=0.38, adjusted

p=0.46) (Supplementary Figure 8). Similarly, participants' perceptions about
understanding their illness were also high (pre-intervention mean 9.2, SD 2.0), without
significant changes after the intervention (p=0.23, adjusted p=0.32) (Supplementary
Figure 9).

225 Sub-Group Analyses

226 Most changes pre- to post-intervention were similar across key sub-groups, with several 227 notable exceptions (Supplementary Table 1). Attitudes about treatment as prevention 228 improved more in the group with the post-intervention interview (mean change -1.2, SD 229 4.3) compared to those who had a pre-intervention interview (mean change 1.3, SD 4.6) 230 (p=0.02), and among participants seen at the community-based site (mean change -1.9, 231 SD 4.7) compared to the clinic-based site (mean change 0.1, SD 4.0) (p=0.02). 232 Perceptions about illness understanding improved more among participants with sub-233 optimal self-reported adherence (mean change 0.6, SD 1.8) compared to those with 234 optimal self-reported adherence (mean change -0.1, SD 1.5) (p=0.03).

235 Qualitative Interviews

Fifty-two participants (44%) completed in-depth interviews — 20 (17%) before the
intervention and 32 (27%) after the intervention.

238 Conceptions of HIV Transmission and Pathogenesis

Most respondents knew that untreated HIV would make them ill; however, others wereunsure about how HIV affects the body.

241 242 243 244 245	I: And what happens once the virus starts taking over those cells? R: You get AIDS, and you become susceptible to all kinds of diseases and everything like that. Your immune system shut down. (Participant 41 – post- intervention)
246 247 248	Well, your white cells deplete, and the HIV starts to take over, killing the white T cells. And eventually it will overcome you and you'll get sick and die. (Participant 19 – pre-intervention)
249 250 251 252 253	What do I think happens inside the body if you have HIV? I'm not exactly sure. What do I think about – sometimes – okay, sometimes I think when you get HIV in your body I think about death, that you're about to die was never taught about the HIV, so that's why – as me finding out what I had, I thought I was going to die right then and there. (Participant 5 – post-intervention)
254	Most respondents from both interview groups knew that HIV is spread through sex or
255	exposure to bodily fluids.
256 257 258 259 260	Because my viral load, it's in my sperm. It's in all the fluids in my body, my blood, my sperm. So passing it on to someone else without any protection for that person, like using a – sharing a needle, intravenous needle, or having unprotected sex or open wounds. You know what I mean? (Participant 6 – post-intervention)
261	Viral Load Suppression
262	Results from the interviews indicated that many respondents in both groups had some
263	understanding of viral suppression.
264 265	Your viral load is very important because your viral load is the one that tell you if you undetectable or not. (Participant 9 – post-intervention)
266 267 268 269	with the treatment, it counts what your viral load is. So if you're on your medicine or whatever treatment that you have to be on, then the more you take your medicine, the less of your viral load. The less viral load you have, to count. (Participant 20 – post-intervention)
270 271 272	Beings though they're taking it regularly, it suppresses a lot of the HIV. Basically, till you're almost – that you have none, really, measurable. (Participant 19 – pre-intervention)
273	Others expressed confusion about the concept of viral suppression.

274 275 276 277 278 279 280	I: What does the concept, viral load, mean to you? R: The viral load? I: Yes. R: I'm not sure in it. Yeah, I'm not sure if I ever knew. I: That's no problem. R: I'm not sure. Neither one, the CD – the CD, what's that? It's the viral load and what else? It's – oh God. (Participant 1 – post-intervention)
281 282 283	Viral load is the blood cells, the white – or I forget which one. It's the white or red. But one has to be high, and one has to be low. I'm not sure which one it is. Right? (Participant 37 – pre-intervention)
284	<u>U=U</u>
285	Most respondents were aware that consistent treatment adherence eliminates the risk
286	of sexual transmission (U=U).
287 288 289 290	Okay. If I'm passing it, you know, if you take your medication every day, you keep your viral load low, you can't pass the disease on to nobody. Because you're undetectable, there's no amount of disease present which causes you to pass on to another person. (Participant 2 – post-intervention)
291 292 293 294	And with the HIV drugs, it kills those new cells or whatever. So the healthy ones can build themselves back up, and once they get back up then you are U=U. You can't pass it on to somebody else. (Participant 11 – post-intervention)
295	However, several respondents expressed uncertainty about U=U —that they thought (or
296	worried) that it was still possible to transmit HIV even with an undetectable viral load.
297 298 299 300	Because I be saying to myself, well, I'm non-detected, I can't pass it on. But I don't think that's true, because as long as it's in my body and I do that sex thing with the blood and that blood-to-blood transfer, I think I could pass it. I believe I can. (Participant 21 – post-intervention)
301	The B-OK Bottles
302	As shown in the quantitative results, respondents reported improved understanding of
303	viral load and the impact of not taking medication after exposure to B-OK.

304	The viral load is what keeps our immune system strong or weak. When we
305	have a very high viral load, it's because our immune system is weakened.
306	That is what the red bottle is for. We have a high viral load. And our body is
307	practically defenseless. We have to take the medication to lower the viral load
308	until it's completely neutralized. (Participant 28 – post-intervention)
309	I learned that – how the HIV is in reference to the first bottle which is a mixture
310	of the dark and the red balls. And the other bottle, which is all red, which
311	meaning that's completely all with HIV up in there, when the dark one means
312	that's the best to have, try to get. (Participant 3 – post-intervention)
313	Well, I didn't know. Since I never seen the cells before, I didn't know that if
314	you're HIV, it's not good. All the cells are being red. But I'm here with the
315	black bottles. I don't want to get in between. (Participant 53 – post-
316	intervention)
317	Respondents felt that the bottle demonstration clearly explained HIV and what would
318	happen if patients stopped taking their medication or took it regularly.
319	Well, it would definitely be very helpful for when [providers] explain about the

Well, it would definitely be very helpful for when [providers] explain about the viral load or about just having HIV and it entering your body, and what it would do if you take your meds, opposed to not. Well, take treatment, opposed to not taking treatment. And I mean, it's a pretty great idea so they – people can understand at all levels. (Participant 50 – post-intervention)

324 **Discussion**

In this mixed methods study of 118 PLWH who were clients of medical case managers in Philadelphia, we found that exposure to B-OK was associated with improved awareness and understanding of HIV terminology, changes in attitudes about HIV treatment, and increased intention to use HIV treatment as prevention. Insights from qualitative interviews aligned with the quantitative results as respondents expressed a better understanding of U=U and felt that B-OK clearly explained concepts of HIV treatment and prevention.

These findings provide evidence supporting the potential for B-OK to improve TAS for PLWH, especially considering the known persistent knowledge gaps about the prevention benefits of ART.¹¹⁻¹³ This potential is further supported by prior randomized controlled
trials that have demonstrated that behavioral interventions designed in part to improve
understanding of treatment as prevention among PLWH can improve ART adherence,
viral suppression, and intentions to rely on treatment as prevention.^{36,37,40}

There were survey questions within some domains that did not improve after exposure to B-OK — in particular, hypothetical scenarios asking participants to estimate the likelihood of sexual transmission from an undetectable partner and the likelihood of harm from HIV for a person with an undetectable viral load, intentions to stay on HIV treatment, and perceived understanding of illness. Participants had very high baseline scores for these questions, so it is unsurprising that there were no significant changes seen after the intervention.

345 Our study population reflected the demographics and racial composition of PLWH in 346 Philadelphia.⁴¹ While we did not collect detailed socioeconomic data, all participants were 347 seen at Ryan White-funded case management sites and therefore met Ryan White 348 eligibility by having income less than 500% of the federal poverty level. Participants 349 generally had long-standing HIV, and had a median age of 55. Our study population was 350 likely to have had adherence challenges at some point based on their engagement with 351 MCMs, and one-third reported current sub-optimal adherence. It is likely that the impact 352 of B-OK could be even greater among younger individuals with more recent (or newly 353 diagnosed) HIV infection and less treatment experience as well as PLWH who have 354 dropped out of care and are not engaging with MCMs. Similarly, it's conceptually plausible 355 that B-OK would be even more effective among PLWH with lower rates of adherence, 356 among PLWH experiencing virological failure, or in populations with low health literacy.

These are also the populations with the greatest need for TAS. This hypothesis is supported by our finding of greater improvements in self-reported illness perception among participants with sub-optimal self-reported adherence.

It is notable that the distributions of most survey responses were highly bimodal, with responses clustered at the extremes and generally a higher peak at the more desired extreme (high self-rated knowledge, greater intention to use HIV treatment as prevention, etc.). This suggests that B-OK may be particularly relevant for the relatively smaller subset of PLWH with incorrect mental models of HIV (i.e., with responses on the less desired extreme), supporting its use as part of a package of interventions for TAS, each targeting different mechanisms of non-adherence.

367 Our study has several important limitations. This was a study designed to assess for 368 preliminary evidence of B-OK effectiveness, and therefore we focused on a population of 369 all-comers at MCM agencies over a short period of time. While these results are 370 promising, it will be important in to evaluate in populations with higher rates of non-371 adherence in future work, with longer term outcomes. It remains unknown whether the 372 changes associated with B-OK identified in this study persist beyond the short-term, and 373 whether these changes would be further reinforced by longitudinal engagement with the 374 bottles. Similarly, we do not yet know whether there will be improvements in clinical 375 outcomes of patients due to any changes in knowledge, attitudes and intentions that occur 376 after exposure to B-OK. These questions should be addressed in future research. Despite 377 this, there is now strong justification to further evaluate B-OK, either alone or as part of a 378 package of interventions, to enhance TAS for PLWH. As part of this study, we also

collected information regarding B-OK acceptability, feasibility, and appropriateness from
 both clients and medical case managers — these findings will be presented separately.

381 Conclusion

382 In this mixed methods study of 118 PLWH who were clients of medical case managers in 383 Philadelphia, we found that exposure to B-OK was associated with improved awareness 384 and understanding of HIV terminology, changes in attitudes about HIV treatment, and 385 increased intention to rely on HIV treatment as prevention as a primary prevention 386 strategy. Qualitative interviews aligned clearly with the survey results as respondents 387 expressed a better understanding of U=U and felt that B-OK clearly explained concepts 388 of HIV treatment and prevention. Our findings provide a strong justification to further 389 evaluate B-OK, either alone or as part of a package of interventions, to improve TAS for 390 PLWH.

391 **Declarations**

392 Ethics approval and consent to participate

- 393 The study was approved by the Institutional Review Board of the University of
- 394 Pennsylvania. Written informed consent was obtained from all participants. One
- 395 participant withdrew from the study and was not included in this analysis.

396 Availability of data and material

- 397 Data are available upon reasonable request to the senior author.
- 398 Competing interests

399 The authors declare no conflicts of interest.

400 Funding

401 This work was funded by a National Institutes of Health Ending the HIV Epidemic

402 Supplement through the Penn Center for AIDS Research Center Grant (P30AI045008)

403 Author's Contributions

- 404 AR, HT, and AB conceived of the study. RC, DP, KV, and GG conducted data collection
- 405 under supervision of AR, LS, and AB. AR conducted quantitative analyses with input from
- 406 HT and AB. ER and DP conducted qualitative analyses under supervision of TK. AR wrote
- 407 the first draft of the manuscript, with critical input from all authors.

408 Acknowledgments

We acknowledge Letitia Rambally Greener, Shawn Malone, and Population Services International, as well as Cal Bruns and Matchboxology for developing and disseminating B-OK. We are grateful to our primary contacts at each of the partner sites for their logistical assistance in completing this work: Terence Carroll and Dr. Amy Althoff at Drexel University, Dr. Ellen Tedaldi at Temple University, Aviva Joffe at Einstein Medical Center, and Nafisah Houston at Bebashi — Transition to Hope.

Table 1. Characteristics of the study population. Data are presented as N (%) unless otherwise specified. N=118 unless otherwise specified.

Age, median (IQR)	55 (47-60)
Male sex	77 (65)
Cis-gender	113 (96)
English primary language (vs Spanish)	110 (93)
Race / Ethnicity	
Hispanic	19 (16)
Non-Hispanic Black	85 (72)
Non-Hispanic White	6 (5)
Other/Multiple	8 (7)
Site	
Bebashi	55 (47)
Drexel	31 (26)
Temple	25 (21)
Einstein	7 (6)
ART	
None	2 (2)
Injectable	9 (8)
Oral	107 (91)
Number of missed oral ART doses in last	0 (0-2)
30 days, median (IQR), N=107	

Abbreviations: ART, antiretroviral therapy

Table 2. Responses on a 0-10 scale (with higher numbers indicating greater agreement) to questions about HIV-related knowledge, attitudes, intentions, and perceptions — baseline score, difference before and after exposure to B-OK, and p-value testing whether the difference was significantly different from zero (single sample t-test, two-tailed, both unadjusted and adjusted for 11 multiple comparisons — Benjamini-Hochberg). Data are presented as mean (SD), N=118.

	Baseline	Difference pre-	p-value	Adjusted	
		post		p-value	
Knowledge					
How well do you understand the term	3.4 (4.1)	2.4 (4.0)	<0.0001	0.001	
"viral suppression?"					
How well do you understand the term	6.6 (4.3)	1.4 (3.7)	0.0001	0.0006	
"U=U" or					
"Undetectable=Untransmittable?"					
Imagine a person living with HIV who	2.1 (3.3)	0.0 (3.6)	0.94	0.94	
is taking HIV treatment and has an					
undetectable viral load. How likely is					
it that this person would pass HIV to					
a regular sexual partner?				0.01	
Imagine a person living with HIV who	2.6 (3.6)	0.1 (3.9)	0.74	0.81	
Is taking HIV treatment and has an					
it that this person would be bermad					
ht that this person would be harmed					
Agrees with I were that I IIV	4 2 (4 2)	0.0 (1.1)	0.05	0.09	
Agrees with. I worry that hiv	4.3 (4.3)	-0.0 (4.4)	0.05	0.08	
aliminate the rick of gotting HIV					
through sex					
Agrees with: Having HIV means I will	31(41)	-0.8 (3.4)	0.008	0.02	
eventually die from it	0.1 (4.1)	-0.0 (0.+)	0.000	0.02	
Intentions					
Imagine you were taking HIV	78(33)	-12(30)	0.0001	0.0006	
treatment and had an undetectable	1.0 (0.0)	1.2 (0.0)	0.0001	0.0000	
viral load. How likely would you be to					
use a condom to prevent passing HIV					
to a sex partner who did not have					
HIV?					
Agrees with: I feel motivated to stay	9.5 (1.8)	0.1 (1.7)	0.38	0.46	
on (or restart) HIV treatment					
Perceptions					
Agrees with: I understand my illness	9.2 (2.0)	0.2 (1.6)	0.23	0.32	
Abbreviations: HIV, human immunodeficiency virus; U=U, Undetectable=Untransmittable					

Figure 1. Proposed conceptual framework illustrating the hypothesized role of B-OK to facilitate treatment adherence support for people with HIV, with the goal of improving clinical outcomes.





Figure 2. Photos of the large and small sets of B-OK Bottles.

Supplementary Appendix

415 Intervention Guide

416 Now I want to show you the B-OK bottles. Please feel free to look at or hold the bottles 417 while I talk. These bottles are to help you understand what is happening inside your body.

418

419 Mix of black and red beads

- First, let's look at this bottle.
- It has a mix of black and red beads.
- The black beads show healthy cells in your body.
- The red beads show the HIV virus.
- This is what it looks like when most people first find out they have HIV, before starting treatment.
- They may feel completely normal, but the red beads show the virus is growing.
- If folks are having sex, they can pass HIV to their partners.
- 428 *Mostly red beads*
- If a person does not start HIV treatment, eventually their body will look like this red
 bottle.
- There are very few healthy black beads left.
- This might happen slow, or it might happen quickly, but it will happen eventually.
- At this stage, it is hard to fight off other sicknesses like cancer and infections.
- Folks often end up in the hospital and can even die.
- 435 *Mostly black beads*
- On the other hand, if a person starts HIV treatment, and takes their treatment every day, their body quickly becomes like this bottle.
- It is full of healthy black beads.
- This is what people mean when they talk about an "undetectable viral load" or a 440 "suppressed viral load."
- You can see there is still one red bead, because there is not yet a cure for HIV.
- However, it is so small and deeply buried that it can't hurt you and it can't be passed on through sex, as long as you keep taking your HIV treatment.
- This is what people mean when they say "Undetectable=Untransmittable" or "U=U"
 that if you are in this stage, you can't pass the virus through sex, even if you don't use a condom.

Supplementary Table 1. Changes in HIV-related knowledge, attitudes, intentions, and perceptions (with higher numbers indicating greater agreement to the questions) by whether participants were interviewed prior to exposure to B-OK, whether participants had optimal (>95%) self-reported adherence, and study site (community-based organization [CBO] vs university). Data are presented as mean (SD), with p-value testing whether changes were different by group (two-sample t-test, two-tailed).

	Interviews			Self-Reported Adherence			Site		
	Pre- Intervention Interview (N=20)	No Pre- Intervention Interview (N=98)	p-value	Optimal (N=73)	Sub- optimal (N=36)	p-value	Community- Based (N=55)	Clinic- Based (N=63)	p-value
Knowledge									
How well do you understand the term "viral suppression?"	2.1 (3.7)	2.5 (4.1)	0.68	2.5 (4.2)	2.3 (3.8)	0.82	2.1 (3.8)	2.7 (4.2)	0.40
How well do you understand the term "U=U" or "Undetectable=Untransmittable?"	0.7 (4.3)	1.6 (3.6)	0.34	1.5 (3.7)	1.3 (3.8)	0.71	1.2 (3.1)	1.6 (4.1)	0.57
Imagine a person living with HIV who is taking HIV treatment and has an undetectable viral load. How likely is it that this person would pass HIV to a regular sexual partner?	1.2 (4.3)	-0.3 (3.4)	0.09	-0.1 (3.9)	0.0 (3.0)	0.90	0.4 (4.4)	-0.4 (2.6)	0.21
Imagine a person living with HIV who is taking HIV treatment and has an undetectable viral load. How likely is it that this person would be harmed by HIV?	-0.2 (3.7)	-0.1 (3.9)	0.92	-0.2 (4.4)	-0.2 (3.1)	0.98	-0.4 (3.8)	0.1 (3.9)	0.46
Attitudes									
Agrees with: I worry that HIV medications do not completely eliminate the risk of getting HIV through sex	1.3 (4.6)	-1.2 (4.3)	0.02	-0.5 (4.8)	-1.3 (3.9)	0.34	-1.9 (4.7)	0.1 (4.0)	0.02
Agrees with: Having HIV means I will eventually die from it	-1.1 (4.3)	-0.8 (3.1)	0.70	-0.6 (3.5)	-1.2 (3.1)	0.40	-0.5 (2.6)	-1.2 (3.9)	0.26
Intentions									
Imagine you were taking HIV treatment and had an undetectable viral load. How likely would you be to use a condom to prevent passing HIV to a sex partner who did not have HIV?	-0.6 (3.7)	-1.3 (2.9)	0.36	-0.9 (3.0)	-1.6 (3.1)	0.28	-1.4 (3.1)	-0.9 (2.9)	0.39
Agrees with: I feel motivated to stay on (or restart) HIV treatment	0.4 (1.4)	0.1 (1.7)	0.44	0.0 (1.9)	0.4 (1.5)	0.31	0.1 (1.9)	0.1 (1.5)	0.96
Perceptions									
Agrees with: I understand my illness	0.2 (1.2)	0.2 (1.7)	0.95	-0.0 (1.4)	0.7 (2.0)	0.04	0.1 (2.0)	0.2 (1.1)	0.75

Supplementary Figure 1. Histogram showing pre- and post-intervention responses on a zero to ten scale to the question: "How well do you understand the term 'viral suppression?"



"How well do you understand the term viral suppression?"

Supplementary Figure 2. Histogram showing pre- and post-intervention responses on a zero to ten scale to the question: "How well do you understand the term 'U=U or Undetectable=Untransmittable?"



"How well do you understand the term U=U or Undetectable=Untransmittable?"

Supplementary Figure 3. Histogram showing pre- and post-intervention responses on a zero to ten scale to the question: "Imagine a person living with HIV who is taking HIV treatment and has an undetectable viral load. How likely is it that this person would pass HIV to a regular sexual partner?"





Supplementary Figure 4. Histogram showing pre- and post-intervention responses on a zero to ten scale to the question: "Imagine a person living with HIV who is taking HIV treatment and has an undetectable viral load. How likely is it that this person would be harmed by HIV?"





Supplementary Figure 5. Histogram showing pre- and post-intervention responses on a zero to ten scale to the question: "Agrees with: I worry that HIV medications do not completely eliminate the risk of getting HIV through sex."



"Agrees with: I worry that HIV medications do not completely eliminate the risk of getting HIV through sex"

Supplementary Figure 6. Histogram showing pre- and post-intervention responses on a zero to ten scale to the question: "Agrees with: Having HIV means I will eventually die from it."



"Agrees with: Having HIV means I will eventually die from it"

Supplementary Figure 7. Histogram showing pre- and post-intervention responses on a zero to ten scale to the question: "Imagine you were taking HIV treatment and had an undetectable viral load. How likely would you be to use a condom to prevent passing HIV to a sex partner who did not have HIV?"



"Imagine you were taking HIV treatment and had an undetectable viral load.

Supplementary Figure 8. Histogram showing pre- and post-intervention responses on a zero to ten scale to the question: "Agrees with: I feel motivated to stay on (or restart) HIV treatment."



"Agrees with: I feel motivated to stay on (or restart) HIV treatment"

Supplementary Figure 9. Histogram showing pre- and post-intervention responses on a zero to ten scale to the question: "Agrees with: I understand my illness."



"Agrees with: I understand my illness"

References

- 1. Centers for Disease Control and Prevention. *Estimated HIV incidence and prevalence in the United States, 2010-2016.* HIV Surveillance Supplemental Report;2019.
- Centers for Disease Control and Prevention. HIV Surveillance Report, 2020; vol. 33. <u>https://www.cdc.gov/hiv/library/reports/hiv-surveillance.html</u>. Published 2022. Accessed 5/2/23.
- 3. United States Department of Health and Human Services. About Ending the HIV Epidemic: Plan for America. <u>https://www.hiv.gov/federal-response/ending-the-hiv-epidemic/overview/</u>. Accessed 2/7/2024.
- Philadelphia Department of Public Health AIDS Activities Coordinating Office. A Community Plan to End the HIV Epidemic in Philadelphia. <u>https://www.phila.gov/media/20201201165516/Ending-the-HIV-Epidemic-in-Philadelphia-A-Community-Plan.pdf</u>. Published 2020. Accessed 5/2/2023.
- 5. Higa DH, Crepaz N, Mullins MM. Identifying Best Practices for Increasing Linkage to, Retention, and Re-engagement in HIV Medical Care: Findings from a Systematic Review, 1996-2014. *AIDS Behav.* 2016;20(5):951-966.
- 6. Kanters S, Park JJ, Chan K, et al. Interventions to improve adherence to antiretroviral therapy: a systematic review and network meta-analysis. *The lancet HIV.* 2017;4(1):e31-e40.
- 7. Cohen MS, Chen YQ, McCauley M, et al. Antiretroviral Therapy for the Prevention of HIV-1 Transmission. *N Engl J Med.* 2016;375(9):830-839.
- 8. Rodger AJ, Cambiano V, Bruun T, et al. Sexual Activity Without Condoms and Risk of HIV Transmission in Serodifferent Couples When the HIV-Positive Partner Is Using Suppressive Antiretroviral Therapy. *Jama*. 2016;316(2):171-181.
- 9. Rodger AJ, Cambiano V, Bruun T, et al. Risk of HIV transmission through condomless sex in serodifferent gay couples with the HIV-positive partner taking suppressive antiretroviral therapy (PARTNER): final results of a multicentre, prospective, observational study. *Lancet.* 2019;393(10189):2428-2438.
- 10. Prevention Access Campaign. Why is U=U important? Published 2020. Accessed 5/2/23.
- 11. Bor J, Onoya D, Richman B, Mayer KH. A Failure to Disseminate Transformative Science -HIV Treatment as Prevention, 10 Years On. *N Engl J Med.* 2021;385(25):2305-2307.
- 12. Bor J, Fischer C, Modi M, et al. Changing Knowledge and Attitudes Towards HIV Treatment-as-Prevention and "Undetectable = Untransmittable": A Systematic Review. *AIDS Behav.* 2021;25(12):4209-4224.
- 13. Philadelphia Department of Public Health AIDS Activities Coordinating Office. Surveillance 2020 - Appendix I: Provider and/or Structural Barrier and Other Barriers Reported by Adults with Diagnosed HIV in Philadelphia at Re-Engagement in HIV Care, 2015-2019. 2021.
- 14. Congres ECU-UCL 2016. Louvain Medical. 2016;135(6).
- 15. Johnson-Laird PN. Mental models and human reasoning. *Proceedings of the National Academy of Sciences of the United States of America*. 2010;107(43):18243-18250.
- 16. Chakrapani V, Newman PA, Singhal N, Nelson R, Shunmugam M. "If It's Not Working, Why Would They Be Testing It?": mental models of HIV vaccine trials and preventive

misconception among men who have sex with men in India. *BMC public health.* 2013;13(1):731.

- 17. Morgan MG, Fischhoff B, Bostrom A, Atman CJ. *Risk communication: A mental models approach.* Cambridge University Press; 2002.
- 18. Lynam T, Brown K. Mental models in human–environment interactions: theory, policy implications, and methodological explorations. *Ecology and Society*. 2012;17(3).
- 19. Downs JS, de Bruin WB, Fischhoff B. Parents' vaccination comprehension and decisions. *Vaccine*. 2008;26(12):1595-1607.
- 20. Kealey E, Berkman CS. The relationship between health information sources and mental models of cancer: findings from the 2005 Health Information National Trends Survey. *J Health Commun.* 2010;15 Suppl 3:236-251.
- 21. Downs JS, de Bruin WB, Fischhoff B, Hesse B, Maibach E. How people think about cancer: A mental models approach. In: *Handbook of risk and crisis communication*. Routledge; 2020:507-524.
- 22. Hanoch Y, Barnes A, Rice T. *Behavioral Economics and Healthy Behaviors: Key concepts and Current Research.* First ed. Routledge.2017.
- 23. Witte K. Extended Parallel Process Model. *The International Encyclopedia of Communication*. 2008.
- 24. Govathson C, Ndlovu N, Rambally-Greener L, et al. Increasing HIV treatment literacy among people living with HIV using a novel health communication aid: Evidence from KwaZulu Natal province, South Africa. In: Cold Spring Harbor Laboratory; 2023.
- 25. Creswell JW, Clark VLP. Chapter 3: Choosing a Mixed Methods Design. In: *Designing and conducting mixed methods research.* Sage publications; 2017:53-106.
- 26. Coach Mpilo B-OK Videos. <u>https://www.coachmpilo.co.za/b-ok-videos</u>. Accessed 7/30/2023.
- 27. Preston CC, Colman AM. Optimal number of response categories in rating scales: reliability, validity, discriminating power, and respondent preferences. *Acta Psychol* (*Amst*). 2000;104(1):1-15.
- 28. Bavinton BR, Holt M, Grulich AE, Brown G, Zablotska IB, Prestage GP. Willingness to Act upon Beliefs about 'Treatment as Prevention' among Australian Gay and Bisexual Men. *PloS one.* 2016;11(1):e0145847.
- 29. Broadbent E, Petrie KJ, Main J, Weinman J. The brief illness perception questionnaire. *J Psychosom Res.* 2006;60(6):631-637.
- 30. Carter A, Lachowsky N, Rich A, et al. Gay and bisexual men's awareness and knowledge of treatment as prevention: findings from the Momentum Health Study in Vancouver, Canada. *J Int AIDS Soc.* 2015;18(1):20039.
- 31. Dewing S, Mathews C, Lurie M, Kagee A, Padayachee T, Lombard C. Predictors of poor adherence among people on antiretroviral treatment in Cape Town, South Africa: a case-control study. *AIDS care*. 2015;27(3):342-349.
- Gottert A, Pulerwitz J, Heck CJ, Cawood C, Mathur S. Creating HIV risk profiles for men in South Africa: a latent class approach using cross-sectional survey data. *J Int AIDS Soc.* 2020;23 Suppl 2(Suppl 2):e25518.

- 33. Kalichman SC, Eaton L, Cain D, Cherry C, Pope H, Kalichman M. HIV treatment beliefs and sexual transmission risk behaviors among HIV positive men and women. *J Behav Med.* 2006;29(5):401-410.
- 34. Okoli C, Van de Velde N, Richman B, et al. Undetectable equals untransmittable (U = U): awareness and associations with health outcomes among people living with HIV in 25 countries. *Sex Transm Infect.* 2021;97(1):18-26.
- 35. Peay HL, Rennie S, Cadigan RJ, et al. Attitudes About Analytic Treatment Interruption (ATI) in HIV Remission Trials with Different Antiretroviral Therapy (ART) Resumption Criteria. *AIDS Behav.* 2022;26(5):1504-1516.
- 36. Kalichman SC, Cherry C, Kalichman MO, et al. Integrated behavioral intervention to improve HIV/AIDS treatment adherence and reduce HIV transmission. *American journal of public health.* 2011;101(3):531-538.
- 37. Kalichman SC, Cherry C, Kalichman MO, et al. Mobile Health Intervention to Reduce HIV Transmission: A Randomized Trial of Behaviorally Enhanced HIV Treatment as Prevention (B-TasP). *Journal of acquired immune deficiency syndromes (1999)*. 2018;78(1):34-42.
- 38. Yekutieli D, Benjamini Y. Resampling-based false discovery rate controlling multiple test procedures for correlated test statistics. *Journal of Statistical Planning and Inference*. 1999;82(1):171-196.
- 39. Chun Tie Y, Birks M, Francis K. Grounded theory research: A design framework for novice researchers. *SAGE Open Med.* 2019;7:2050312118822927.
- 40. Derksen L, Muula A, van Oosterhout J. Love in the Time of HIV: Testing as a Signal of Risk. *Natural Field Experiments.* 2016;550.
- 41. Philadelphia Department of Public Health AIDS Activities Coordinating Office. *Surveillance report, 2020.* Philadelphia, PA: City of Philadelphia;2021.